glp-1 news september 30 2025 Americans turn to risky unregulated sellers for weight-loss drugs The expanding landscape of GLP-1

Lisdexamfetamine, a dopaminergic pro-drug metabolized to dexamphetamine, was approved by the FDA for ADHD

First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health

Each compound has its own stability profile based on its molecular structure, formulation, and the data available from stability testing

But the research supporting these and other natural weight-loss alternatives is limited

doi: 10.1097/HJH.0000000000001825 7 MallamaciFTripepiGD'ArrigoGBorrelliSGarofaloCStanzioneGet al

But the authors of this analysis are hoping to use it as the foundation for future clinical trials